190 related articles for article (PubMed ID: 24482120)
21. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
[TBL] [Abstract][Full Text] [Related]
22. The G2019S LRRK2 mutation: another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease.
Melamed E
Mov Disord; 2013 Dec; 28(14):1912-4. PubMed ID: 24307480
[No Abstract] [Full Text] [Related]
23. Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study.
Vilas D; Segura B; Baggio HC; Pont-Sunyer C; Compta Y; Valldeoriola F; José Martí M; Quintana M; Bayés A; Hernández-Vara J; Calopa M; Aguilar M; Junqué C; Tolosa E;
Mov Disord; 2016 Dec; 31(12):1820-1828. PubMed ID: 27653520
[TBL] [Abstract][Full Text] [Related]
24. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
[TBL] [Abstract][Full Text] [Related]
25. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981
[TBL] [Abstract][Full Text] [Related]
26. Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease.
Lesage S; Leclere L; Lohmann E; Borg M; Ruberg M; Dürr A; Brice A;
Neurodegener Dis; 2007; 4(2-3):195-8. PubMed ID: 17596714
[TBL] [Abstract][Full Text] [Related]
27. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease.
Kalinderi K; Fidani L; Bostantjopoulou S; Katsarou Z; Kotsis A
Eur J Neurol; 2007 Oct; 14(10):1088-90. PubMed ID: 17880562
[TBL] [Abstract][Full Text] [Related]
28. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort.
Bras JM; Guerreiro RJ; Ribeiro MH; Januario C; Morgadinho A; Oliveira CR; Cunha L; Hardy J; Singleton A
Mov Disord; 2005 Dec; 20(12):1653-5. PubMed ID: 16149095
[TBL] [Abstract][Full Text] [Related]
29. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
[TBL] [Abstract][Full Text] [Related]
30. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.
Latourelle JC; Sun M; Lew MF; Suchowersky O; Klein C; Golbe LI; Mark MH; Growdon JH; Wooten GF; Watts RL; Guttman M; Racette BA; Perlmutter JS; Ahmed A; Shill HA; Singer C; Goldwurm S; Pezzoli G; Zini M; Saint-Hilaire MH; Hendricks AE; Williamson S; Nagle MW; Wilk JB; Massood T; Huskey KW; Laramie JM; DeStefano AL; Baker KB; Itin I; Litvan I; Nicholson G; Corbett A; Nance M; Drasby E; Isaacson S; Burn DJ; Chinnery PF; Pramstaller PP; Al-hinti J; Moller AT; Ostergaard K; Sherman SJ; Roxburgh R; Snow B; Slevin JT; Cambi F; Gusella JF; Myers RH
BMC Med; 2008 Nov; 6():32. PubMed ID: 18986508
[TBL] [Abstract][Full Text] [Related]
31. Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?
Duncan GW; Firbank MJ; Yarnall AJ; Khoo TK; Brooks DJ; Barker RA; Burn DJ; O'Brien JT
Mov Disord; 2016 Jan; 31(1):103-10. PubMed ID: 26202802
[TBL] [Abstract][Full Text] [Related]
32. LRRK2 G2019S founder haplotype in the Chinese population.
Tan EK; Skipper L; Tan L; Liu JJ
Mov Disord; 2007 Jan; 22(1):105-7. PubMed ID: 17083102
[TBL] [Abstract][Full Text] [Related]
33. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
Alcalay RN; Mejia-Santana H; Mirelman A; Saunders-Pullman R; Raymond D; Palmese C; Caccappolo E; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K;
Parkinsonism Relat Disord; 2015 Feb; 21(2):106-10. PubMed ID: 25434972
[TBL] [Abstract][Full Text] [Related]
34. G2019S LRRK2 mutation in French and North African families with Parkinson's disease.
Lesage S; Ibanez P; Lohmann E; Pollak P; Tison F; Tazir M; Leutenegger AL; Guimaraes J; Bonnet AM; Agid Y; Dürr A; Brice A;
Ann Neurol; 2005 Nov; 58(5):784-7. PubMed ID: 16240353
[TBL] [Abstract][Full Text] [Related]
35. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.
Ben Sassi S; Nabli F; Hentati E; Nahdi H; Trabelsi M; Ben Ayed H; Amouri R; Duda JE; Farrer MJ; Hentati F
Parkinsonism Relat Disord; 2012 Mar; 18(3):243-6. PubMed ID: 22056842
[TBL] [Abstract][Full Text] [Related]
36. Clinical heterogeneity of the LRRK2 G2019S mutation.
Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
[TBL] [Abstract][Full Text] [Related]
37. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
38. Alterations of mean diffusivity in brain white matter and deep gray matter in Parkinson's disease.
Kim HJ; Kim SJ; Kim HS; Choi CG; Kim N; Han S; Jang EH; Chung SJ; Lee CS
Neurosci Lett; 2013 Aug; 550():64-8. PubMed ID: 23831353
[TBL] [Abstract][Full Text] [Related]
39. Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy.
De Rosa A; Criscuolo C; Mancini P; De Martino M; Giordano IA; Pappatà S; Filla A; De Michele G
Parkinsonism Relat Disord; 2009 Mar; 15(3):242-4. PubMed ID: 18621566
[TBL] [Abstract][Full Text] [Related]
40. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
